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A B S T R A C T
Objective: Previous studies suggested a higher risk of all-cause mortality in patients with epilepsy than in
the general population. However, information on the age- and sex-speciﬁc risk of mortality, as well as on
the cause-speciﬁc risk of mortality has been sparse. This study aims to determine sex-, age-, and cause-
speciﬁc risk of mortality among patients with epilepsy from southern Taiwan.
Methods: A total of 2180 patients treated in a tertiary hospital in southern Taiwan between 1989 and
2008 were compared to the general population of Taiwan for age-, sex- and cause-speciﬁc mortalities.
The age-, sex-, and calendar year-standardized mortality ratios (SMRs) were calculated to estimate the
relative risks of mortality associated with the epilepsy.
Results: There are 266 (12.2%) deaths noted in the study period. The patients with epilepsy experienced a
signiﬁcantly increased SMR of all-cause mortality (SMR, 2.5; 95% conﬁdence interval (CI), 2.2–2.8). The
most signiﬁcantly elevated age-speciﬁc SMR was 51.8 (95% CI, 6.2–187.2) and 8.6 (95% CI, 4.4–14.9) for
male patients aged 0–9 years and female patients aged 20–29 years, respectively. Additionally, the most
increased cause-speciﬁc SMR was noted for brain tumor (SMR, 21.4; 95% CI, 9.23–23.1), followed by
accidental drowning (SMR, 8.8; 95% CI, 3.5–9.6) and falls (SMR, 5.7; 95% CI, 2.2–6.1).
Conclusion: Younger epilepsy should be the object of aggressive treatments. Advancement in treating
brain tumors and prevention of accidental injuries may help improve the survival of patients with
epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Mortality in people with epilepsy exceeds that in the general
population,1–5 which is especially true for certain causes of death
including cerebrovascular disease (CVD),2,3,6 neoplastic disor-
ders,2,3,6 pneumonia,2,3 poisoning,7 and suicide.8–10 In a recent
review, Neligan et al. examined the temporal trends in the
mortality of people with epilepsy and noted that the standardized
mortality ratio (SMR) of mortality is highest in the initial years
after diagnosis11; and there is no evidence that either the overall
SMR or the mortality rate of people with epilepsy has changed
signiﬁcantly over time. Compared to the general population, the
SMR for all-cause deaths varied from 1.6 to 5.3,12 and the variation
in cause-speciﬁc SMRs is usually grater. Common causes of deaths
were also observed in certain selected epilepsy populations where
patients with frequent and severe seizures are more common, and* Corresponding author at: Department of Public Health, College of Medicine,
National Cheng-Kung University, 1 University Road, Tainan 701, Taiwan.
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1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2012.01.006the SMRs for these selected epilepsy populations are three to six
fold higher compared to those noted in population-based
studies.7,13–18 Although an increased mortality risk of all accidents
was also noted in patients with epilepsy,2,7,14,19 information
concerning risk of death from speciﬁc cause of accidental death,
such as drowning20 and driving fatalities21 has been neither
comprehensive nor consistent, mainly due to certain methodolog-
ical problems including small sample size and employment of
patients with varying frequency of seizures.
Despite that the excess mortality in people with epilepsy has
been well documented in the literature, most of studies were
conducted in European and North American nations.12,13,22 While
there were data on prevalence of epilepsy from some developing
countries, there is little information on the mortality of epilepsy in
these populations. Limited information concerning mortality from
epilepsy was available in developing countries, which was mainly
due to the fact that death certiﬁcates are usually unreliable and
often unavailable, and the cause of death is difﬁcult to determine in
many developing countries.23 Meanwhile, information on mortal-
ity risk associated with epilepsy has also been rarely reported in
Asian nations including Taiwan.24,25 A community-based survey of
13,663 subjects aged 30 years or older reported an active epilepsy
prevalence of 3.8/1000 in Taiwan, and the lifetime prevalence ratevier Ltd. All rights reserved.
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was estimated at 3.14/1000 for age above 30 years. In comparison
with prior surveys, the study also indicated that the prevalence
rate of epilepsy was rather stable over the in recent two decades.26
Concerning the mortality risk, there have been only two hospital-
based studies carried out to investigate the risk of mortality in
Taiwanese patients with epilepsy.24,25 Due to small sample size,
interpretation of cause-speciﬁc mortality risk is rather limited, and
reliable mortality risk estimates for detailed age and sex
stratiﬁcations were not likely. We therefore conducted this cohort
study with a larger cohort of people with epilepsy recruited from a
tertiary hospital in southern Taiwan. With a sufﬁcient number of
study subjects, this study aims to investigate the sex, age, and
cause-speciﬁc mortality risk associated with epilepsy in Taiwan.
Results from this study were also compared with ﬁndings from
other nations globally.
2. Subjects and methods
Between 1989 and 2008, a total of 2180 prevalent epilepsy
patients, including 1214 men and 966 women, were treated at a
tertiary hospital in southern Taiwan. We reviewed medical charts
of those patients for their demographic characteristics and clinical
manifestations of the disease. The charts included personal
identiﬁcation number (PIN), gender, date of birth, and date of
the initial diagnosis of epilepsy. Information on seizure type and
diagnosis was ascertained according to the guidelines recom-
mended by the Commission on Epidemiology and Prognosis of the
International League against Epilepsy.27
The cohort was then linked, using PIN, to Taiwan Death Register
(TDR) between 1989 and 2008. The TDR is considered accurate and
complete because it is mandatory to register all deaths in Taiwan
and for physicians to complete all death certiﬁcates.28 The linkage
showed that 266 patients died by the end of 2008. Information on
date of death and underlying cause of death (UCOD) coded
according to the International Classiﬁcation of Diseases 9th or 10th
Clinical Modiﬁcation (ICD-9-CM for 1988–2007 and ICD-10-CM for
2008) were retrieved from the TDR.
We compared patients’ risks of overall and age- and sex-speciﬁc
mortality to those of the general population. We also compared the
risks of mortality from various causes including malignant
neoplasms (ICD codes: 140–208 & C00-C97), heart disease (ICD
code: 398, 402, 416, 425, 427–428 & I09, I11, I27, I42, I49, I50),
ischemic heart disease (ICD codes: 410–414 & I20-I25), cerebro-
vascular disease (ICD codes: 430–438 & I60-I69), pneumonia (ICD
codes: 480–486 & J12-J18), liver cirrhosis (ICD codes: 571 & K70,
K73-K74), and injury (ICD code: E800-E999 & V01-Y89) between
the patients with epilepsy and the general population. The
expected number of death for the epileptic cohort was calculated
from the person-year approach, using the age (10-year intervals)
and sex-speciﬁc annual mortality rates with reference to the
general population. We ﬁrst calculated the number of person-years
being observed for each study subject. The date of study entry was
the date of initial primary or secondary diagnosis as epilepsy
during the study period, i.e., 1989–2008. The date of completion of
follow-up was the date of death encountered by the study subjects
who died prior to the end of 2008. For those who were intact during
the study period, the date of end-of-follow-up was set to be
December 31, 2008. The annual age-sex-speciﬁc population sizes
for the general population during the study period were derived
from the national annual household registration statistics pub-
lished by Ministry of the Interior of Taiwan. Standardized mortality
ratios (SMRs) were calculated as relative risk estimates. The
average annual average size of the general population over the
study period was 21,769,198. The 95% conﬁdence interval (CI) for
SMR was estimated using the exact estimation.29,30 The analysiswas performed using SAS (version 9.1; SAS Institute, Cary, NC), and
level of signiﬁcance was set at a p-value of 0.05. The National
Cheng Kung University Medical School IRB has approval of this
study (ER-98-065).
3. Results
The study cohort consisted of 1214 male subjects and 966
females. The age ranged from 0 to 82 years at the ﬁrst appearance
in the cooperative hospital, with a median and mean (SD) age of
15 and 21  16 years old, respectively. Over a maximum of nearly 20
years of follow-up, a total of 22,617 person-years were accumulated.
The length of follow-up varied, ranging from 0 to 4 years (n = 423), 5
to 9 years (n = 601), 10 to 14 years (n = 664), and 15 years and longer
(n = 492). Totally, 266 deaths (193 men and 73 women) were noted at
the end of follow-up. The mean age at death was 50 years (SD = 19
years) for all 266 deceased subjects.
Table 1 shows the overall and age- and sex-speciﬁc SMRs of all-
cause mortality. The overall SMR was signiﬁcantly increased for
patients with epilepsy (SMR, 2.5; 95% CI, 2.2–2.8). Both male and
female patients had a very similar risk estimate. The age-speciﬁc
SMR was also signiﬁcantly increased in patients with epilepsy of all
age groups except those aged 10–19 and 70+ years. The most
elevated SMR was noted in young children epilepsy aged 0–9 (SMR,
34.0; 95% CI, 4.1–122.8) followed by those aged 20–29 years (SMR,
6.3; 95% CI, 4.4–8.7). The age-sex-speciﬁc analysis showed that the
most increased SMR for male patients was noted in children
patients aged 0–9 years (SMR, 51.8; 95% CI, 6.2–187.2) followed by
those aged 20–29 years (SMR, 5.6; 95% CI, 3.5–8.2), while patients
aged 20–29 years were at the most elevated risk of mortality (SMR,
8.6; 95% CI, 4.4–14.9) in females.
The cause-speciﬁc SMRs are shown in Table 2. The SMR of all
malignant neoplasm was signiﬁcantly increased at 1.7 (95% CI, 1.2–
1.7). The cancer-speciﬁc analysis further indicated a substantially
and signiﬁcantly increased SMR for brain tumor (SMR, 21.4; 95% CI,
9.2–23.1). We also noted a signiﬁcantly increased SMR for liver
cancer (2.6; 95% CI, 1.4–2.7). In addition to malignant neoplasm,
heart disease (SMR, 2.6; 95% CI, 1.2–2.7), cerebrovascular disease
(SMR, 2.6; 95% CI, 1.6–2.6) and pneumonia (SMR, 2.5; 95% CI, 1.1–
2.7) were all signiﬁcantly and positively associated with epilepsy
mortality. On the other hand, we found no signiﬁcant association of
epilepsy with mortality from ischemic heart disease or liver
cirrhosis. Patients with epilepsy were also at a signiﬁcantly
increased SMR for all injuries (SMR, 3.6; 95% CI, 2.7–3.6), as well as
for certain injuries including transport accidents (SMR, 2.5; 95% CI,
1.4–2.6), accidental falls (SMR, 5.7; 95% CI, 2.2–6.1), accidental




In 22,617 person-years observed over nearly 20 years, we noted
an SMR of 2.5 for all-cause mortality in our sample patients, with a
slightly higher risk estimate for men (SMR = 2.6) than for women
(SMR = 2.2). In the age-speciﬁc analysis, our study noted a
remarkably increased risk of mortality in younger patients with
epilepsy. Like ﬁndings from the studies of many developed nations,
our study also noted that Taiwanese people with epilepsy were
also at signiﬁcantly elevated risk of mortality from non-injury
causes including malignant neoplasm (especially form brain
tumor), cerebrovascular disease, pneumonia, and suicide, with
an SMR ranging from 1.7 for malignant neoplasm (21.4 for brain
tumor) to 2.6 for cerebrovascular disease. Additionally, SMRs for
certain injury related causes, such as drowning (8.8) and fall (5.7)
Table 1
Standardized mortality ratio (SMR) for patients with epilepsy.
Age (year) Sex No. of patients No. of person-years No. of deaths SMRa 95% CI
Observed Expected
0–9 Male 54 104 2 0.04 51.8 6.2–187.2
Female 33 71 0 0.02 –
Total 87 174 2 0.06 34.0 4.1–122.8
10–19 Male 293 1251 2 0.77 2.6 0.3–9.4
Female 223 923 0 0.27 0.0 0–13.7
Total 516 2173 2 1.04 1.9 0.2–6.9
20–29 Male 338 3690 24 4.32 5.6 3.5–8.2
Female 313 2962 12 1.40 8.6 4.4–14.9
Total 651 6652 36 5.72 6.3 4.4–8.7
30–39 Male 208 2954 35 6.45 5.4 3.7–7.5
Female 175 2637 10 2.10 4.8 2.2–8.7
Total 383 5590 45 8.55 5.3 3.8–7.0
40–49 Male 159 2158 38 9.46 4.0 2.8–5.5
Female 111 1776 13 2.97 4.4 2.3–7.4
Total 270 3934 51 12.43 4.1 3.0–5.3
50–59 Male 65 1260 31 10.74 2.9 1.9–4.0
Female 50 965 7 3.70 1.9 0.7–3.8
Total 115 2225 38 14.44 2.6 1.8–3.6
60–69 Male 54 555 22 10.62 2.1 1.2–3.1
Female 39 420 10 4.47 2.2 1.0–4.1
Total 93 975 32 15.08 2.1 1.4–2.9
70+ Male 39 525 39 31.10 1.3 0.8–1.7
Female 20 369 21 17.73 1.2 0.7–1.8
Total 59 893 60 48.83 1.2 0.9–1.5
All Male 1214 12,495 193 73.48 2.6 2.2–3.0
Female 966 10,121 73 32.67 2.2 1.7–2.8
Total 2180 22,617 266 106.15 2.5 2.2–2.8
CI, conﬁdence interval.
a Overall SMR was standardized for age, sex, and calendar year; age-speciﬁc SMR was standardized for sex and calendar year; sex-speciﬁc SMR was standardized for age
and calendar year; age-sex-speciﬁc SMR was standardized for calendar year.
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also provided support for an increased risk of mortality from
suicide and transport accidents in patients with epilepsy, with
an SMR of 4.0 and 2.5, respectively. Given that the SMRs for all-
cause mortality ranged from 1.6 to 5.3 in most previous
community-based studies, and tended to be higher in studies
of selected population (3.2–7.9),12 the patients with epilepsy in
southern Taiwan experienced essentially the same magnitude ofTable 2
Cause-speciﬁc standardized mortality ratio (SMR) in patients with epilepsy.
Cause of death (ICD-9-CM code & ICD-10-CM) 
Malignant neoplasm (140–208 & C00-C97) 
Malignant neoplasm of liver (155 & C22) 
Malignant neoplasm of lung (162 & C34) 
Brain tumor (191& C71) 
Malignant neoplasm except brain tumor (140–208, excluding191 & C00-C97 exclu
Heart disease (398, 402, 416, 425, 427–428 & I09, I11, I27, I42, I49, I50) 
Ischemic heart disease (410–414 & I20-I25) 
Cerebrovascular disease (430–438 & I60-I69) 
Pneumonia (480–486 & J12-18) 
Liver cirrhosis (571 & K70, K73-K74) 
Accidents and injury (E800-E999 & V01-Y89) 
Motor vehicle trafﬁc accident (E800-E848 & V01-V99) 
Accidental falls (E880–E888 & W00-W19) 
Accidental drowning (E910& W65-W74) 
Suicide (E950-E959 & X60-X84) 
CI, conﬁdence interval.increased risk of mortality, as compared to the general
Taiwanese population.
4.2. Age and sex-speciﬁc SMR
Although highest in the younger patients, the SMR was
signiﬁcantly increased in all age groups before 70 years. Like
many previous studies,7,13 our study also found an inverse relationNo. of deaths SMR 95% CI
Observed Expected
48 28.1 1.7 1.2–1.7
15 5.8 2.6 1.4–2.7
6 5.2 1.1 0.4–1.2
8 0.4 21.4 9.2–23.1
ding C71) 40 27.7 1.4 1.0–1.4
10 3.9 2.6 1.2–2.7
4 4.9 0.8 0.2–0.9
25 9.8 2.6 1.6–2.6
9 3.6 2.5 1.1–2.7
10 4.9 2.1 0.9–2.1
55 15.2 3.6 2.7–3.6
15 6.0 2.5 1.4–2.6
7 1.2 5.7 2.2–6.1
7 0.8 8.8 3.5–9.6
14 3.5 4.0 2.1–4.1
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while decreasing SMRs were found with increasing age. A recent
study reported that childhood-onset epilepsy was associated with
a substantially higher risk of epilepsy-related death, including
sudden and unexplained death.31 The study by Sillanpa¨a¨ et al. also
noted that younger patients with epilepsy had a greater risk of
mortality from suicide.31 Previous studies noted that the risk of
suicide is even greater in epilepsy youth with depression,32 and the
prevalence of depression and anxiety in children and adolescents
with epilepsy was considered high.33 Moreover, previous studies
reported that young people with epilepsy tended to have poor
compliance with antiepileptic treatment and adopt behaviors that
could increase their risk of mortality from epilepsy, for example,
using alcohol and recreational drugs that may lower their seizure
threshold.34 Alternatively, the high SMR in children and young
adults with epilepsy could simply be a reﬂection of both the low
mortality in the reference population and high mortality in
patients suffering from epilepsy.35,36 We further examined the
UCOD for the two boys (<10 years) who died in our study. The two
boys died of septicemia (ICD-9: 038) at 5 years old and epilepsy
and recurrent seizures (ICD-9: 345) at age of 8, respectively. Based
on such small numbers of death and person-years observed in this
age category, we were unable to look into the possible causes for
the substantially increased SMR in young children. Meanwhile, we
could not exclude the possibility that the substantially high SMR
noted in young children was due to random variation in risk
estimates, represented by a wide conﬁdence interval of SMR.
Most studies1,2,4,6 observed a higher mortality risk in epilepsy
males than in their female counterparts. However, compared to the
general population of the same gender, our data showed only small
difference in sex-speciﬁc SMR for adult patients, but still presented
some variations in sex-speciﬁc SMR for children and young adults
albeit the risk estimates were based on very small number of
young patients. Given a small sample size for young epilepsy,
further interpretation for the potential effect-modiﬁcation by age
on the sex-speciﬁc SMR is rather limited. As nearly all studies
found lower mortality in patients in the category of unknown
etiology (i.e., idiopathic) than in those patients in the remote
symptomatic group including progressive CNS disorders such as
brain tumors and neurodegenerative disorders, the observed small
difference in sex-speciﬁc SMR might be attributable to a higher
prevalence of certain progressive CNS disorders in males.37 Further
studies are needed to address whether there is an interactive
effects of age and sex on the risk of mortality from epilepsy.
4.3. Cause-speciﬁc SMR
Our study ﬁndings are generally consistent with previous
ﬁndings that people with epilepsy are at greater risks of mortality
from cerebrovascular disease (CVD),2,3,6 neoplasm (especially
brain cancer),2,3,6 pneumonia,2,3 and suicide.8–10 Nonetheless,
our study also noted an increased risk of mortality from certain
speciﬁc causes such as liver cancer, heart disease, and some injury
related causes, which deserved further comments.
One earlier Taiwanese study by Chen et al. of adult patients with
epilepsy found that the patients with epilepsy had a 3.5-fold higher
risk of death as compared to the general population (SMR: 3.47,
95% CI, 2.46–4.91).24 Chen et al.’s study also noted that patients
with late disease onset (40 years) had a 4-fold higher risk of death
as compared to those with an earlier onset.24 This earlier study also
observed that one-third of the deaths in patients with age-at-onset
between 40 and 59 years died of liver cirrhosis and hepatoma. A
higher risk of liver cancer noted in our study could be due to the
fact that Hepatitis B virus infection is endemic in Taiwan, and this
is closely associated with liver cirrhosis and hepatoma.24 It is not
clear by far whether anticonvulsants might contribute to thehepatotoxicity leading to fatal liver disease in patients with
epilepsy.24 Previous studies suggested that intake of antiepileptic
drugs (AEDs) might increase the risk of some malignancies,
particularly lung cancer, hepatobiliary and pancreatic tumors.
However, our study found no increased SMR for lung cancer in
patients with epilepsy in Taiwan.
The patients with epilepsy in our sample experienced a 3-fold
higher risk of mortality from heart disease, which is rarely reported
in the literature. Nilsson et al. followed more than 9000 patients
admitted for epilepsy and observed 4001 deaths in the cohort.7 The
excess mortality rate in the cohort was due to a wide range of
causes of death, including diseases of the circulatory system with a
SMR similar to ours at 3.1 (95% CI, 3.0–3.3). Benn et al. determined
underlying cause-speciﬁc mortality for incident unprovoked
seizures from Northern Manhattan, New York City, and noted
that about 25.0% of the death were attributed to heart, second to
the proportion of malignant neoplasm (31.3%).38 A recent
Norwegian study found that both epileptic men and women using
carbamazepine (CBZ) had higher total cholesterol, high-density
lipoprotein and low-density lipoprotein than controls. They also
found that patients with epilepsy recorded less physical activity
and lower alcohol use than controls.39 Further studies are needed
to investigate whether medication for treating epilepsy and
lifestyle may play certain roles in causing cardiovascular disease
in patients with epilepsy.
Apart from a higher risk of suicide death noted in epilepsy,
which has been well documented in the literature and has been
attributable to a high prevalence of psychiatric comorbidity noted
in patients with epilepsy,10,40 our study also disclosed a higher
SMR for motor vehicle trafﬁc accident, accidental falls and
accidental drowning and submersion, with substantially high
SMRs (8.0–9.0 fold higher) for the later two causes. It has been
reported that people with epilepsy are not injured in trafﬁc
accidents more often than are those in the general population, and
the trafﬁc accidents happened to epilepsy patients tend to be less
severe.7 A recent study reported that an average of 44,027 US
drivers died annually as a result of motor vehicle crashes during
1995–1997; however, only 86 (0.2%, range 82–97) of these deaths
were associated with seizures in mortality reports.21 Unlike those
previous studies which provided reassurance for the public policy,
adopted in some nations but not in all, of permitting patients
whose seizures are controlled to drive, our results suggested
caution and imposed certain conditions in issuing driver’s licenses.
Although people with conﬁrm diagnosis of epilepsy are not
allowed by law to possess a driver’s license in Taiwan, it is believed
that many epilepsy patients are still driving in areas where the
public transportation is inadequate. Due to limited information,
we were not able to further assess how many patients with
epilepsy who died of motor vehicle crashes in our sample truly had
their epilepsy satisfactorily controlled.
People with epilepsy are thought to be at an increased risk of
accidental falls and drowning.20,41,42 Epilepsy associated handi-
caps and comorbidity and antiepileptic drugs may cause accidents
and injuries by impairing cognitive functions and increasing the
patient’s susceptibility to suffer from the complications of
injuries.41 Petty et al. investigated chronic AED use and physical
contributors to falls risk in treated epilepsy patients, and noted
that balance performance is impaired in AED users.42 In a recent
meta-analysis, Bell et al. reported that the risk of drowning in
people with epilepsy is raised 15–19-fold compared with the
general population.40 This summary relative risk estimate for
drowning is much higher than ours (SMR = 8.0). The lower risk
estimates for accidental drowning noted in our study patients
might reﬂect lower prevalence of the above risk factors for
impaired cognitive functions in patients with epilepsy from
southern Taiwan.
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This study has several methodological strengths. First, our
study was based on clinical series of patients from a tertiary
hospital, which may provide valid data on the diagnosis of
epilepsy. Thus, our study was less likely to incur disease
misclassiﬁcation bias. Second, with a sufﬁcient large size, we
were able to make age, sex, and cause speciﬁc analyses without
comprising the statistical power, which also allowed more speciﬁc
interpretations of the study ﬁndings. Third, we linked our study
cohort to the national death registry. This way of doing effectively
reduced the likelihood of selection bias resulting from patients’
loss to follow-up. Despite the above strengths, several limitations
should also be stated. First, the study cohort was consisted only of
prevalent cases that sought treatment in hospitals, and was unable
to include the patients who did not seek treatments or who died
soon after disease onset prior to receiving treatment in the
cooperation hospital. It is generally agreed that incident cohort
differs from the prevalent cohort in many ways. Prevalent cohorts
might underestimate short-term mortality because the more
serious cases die in the early phase of the disease and are not
included in the calculation of deaths over the period of
observation.43 Our study included prevalent cases, which might
under-ascertainment of deaths from epilepsy. Second, our study
sample was selected from a tertiary hospital, which might have
limited the external validity of the results due to the fact that the
patients admitted or cared in medical centers are often highly
selected.14,44,45 Third, reliance on death registry in the ascertain-
ment of causes of death may limit our interpretations of study
results since the causes of death certiﬁed on the death certiﬁcate
for the deaths of epilepsy patients may not necessarily be epilepsy
related.25 Moreover, because we were not allowed to contact the
patients or their family members, or to review patient’s medical
charts, we were unable to validate the UCOD for the deceased
subjects. Despite that, the TDR has been considered accurate and
complete,28 therefore, the potential disease misclassiﬁcation and
under-ascertainment should be minimal; and such disease
misclassiﬁcation is likely to be non-differential, which may lead
to under-estimation of effects of epilepsy on mortality, and should
not be a valid argument for the signiﬁcant increased risk of
mortality in people with epilepsy observed in this study. Fourth,
due to a lack of information on lifestyle, it is not possible for our
study to evaluate the roles, if any, of certain risk factors for
neoplasm and cerebrovascular disease in causing death in patients
with epilepsy. For example, there could be a difference between
the smoking habits of people with epilepsy and the general
population, and an increased smoking or alcohol intake might be to
blame for the increased mortality risk in patients with epilepsy.
Fifth, recent studies suggested that the risk of premature death
remains signiﬁcantly elevated at 20–25 years after the index
seizure in people with epilepsy,46 our study was also limited in its
length of follow-up. An extension of follow-up period in future
studies should be considered to further depict the long-term risk of
mortality in people with epilepsy. Last, as an end-point, we used
mortality data rather than incidence data. Thus, the concepts of
risk and prognosis are mixed.
5. Conclusions
The SMR of all-cause mortality was signiﬁcantly increased in
patients with epilepsy from southern Taiwan. Such increase in risk
was especially noticeable in younger patients, who should be the
object of aggressive treatments. Effective measures for preventing
mortality from injury related causes should be formatted to further
reduce the excess of premature deaths for the patients with
epilepsy in Taiwan.References
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